Four dairy goats in the second to third month of lactation were administered [14 C]-Aflatoxin B 1 ( [14 CI -AFB ~ ). Two goats were dosed intravenously (iv) with 130 #Ci (182 gCi/#mol) and two were dosed orally with 196 #Ci (256 #Ci/#mol). Urine, milk and feces were collected for 120 h after [14Cl-AFB1 administration. Recoveries (average of two animals) of 14C in urine, milk and feces were, respectively; 22.7, .97 and 65% (iv dose) and 30.9, 1.05 and 52.3% (oral dose). Aflatoxin M 1 (AFM 1 ) was found in milk in the highest concentration. Aflatoxin Qa (AFQ 1 ) and aflatoxicol (AFL) were found in trace quantities in milk of animals administered the oral dose. In general, AFM 1 could account for the majority of dicholromethane-soluble 14 C. Liver contained 7.3 and 4.9% of the dose after 120 h for the iv and oral doses respectively. Kidney, heart, lung and spleen all contained .1% or less of the dose at 120 h. Muscle contained .48% of the dose at 120 h from the goats administered [14Cl -AFB 1 orally. There was no detectable radioactivity in the fat of any goat at 120 h.
Introduction
Aflatoxins are extremely toxic compounds. Aflatoxin (AF) B1 has been shown to be carcinogenic at levels of 1 ppb in the diet of the rat (Wogan et al., 1974) . Aflatoxins are transmitted from feed of lactating animals to milk. Investigations of this transfer, in general, have been limited to the detection of Aflatoxin MI (AFM1) in milk (Alleroft and Roberts, 1968; Masri et al., 1969; Purchase, 1972; Patterson et al., 1980) . Transmission of AFM1 from feed to milk is variable, ranging from .3 to 2.2% (Stoloff, 1979; Patterson et al., 1980) . These transmission data are limited because they consider only a milk-to-feed percentage ratio and chloroform-soluble metabolites.
Several studies have been conducted using ring-labeled [14C]-AFB1 in simple-stomached animals. The majority of radioactivity was eliminated via urine and feces. Rats (Wogan et al., 1967) , monkeys (Dalezios et al., 1973) and pigs (Luthy et al., 1980) excreted 75, 72, and 70% via urine plus feces, respectively. The majority of AFBI metabolites recovered in urine and feces were in the aqueous and nonspecifically bound fractions. Excretory patterns were reported to differ in ruminants. Polan et al. (1974) fed lactating dairy cows [3H]-AFB1 and monitored 3H appearance in urine, milk and feces for 96 h. Recoveries of radiolabel expressed as cumulative percentages of administered dose were 3.4, 5.0 and 1.7 from urine, feces and milk, respectively, accounting for less than 15% of the radiolabel from AFB1. They suggested that tritium not accounted for was retained in tissues.
The current study was undertaken to determine the transmission and identity of aflatoxin metabolites from lactating animals administered [14C] -AFBI. ment of Animal Science, Small Animal Colony, University of California at Davis. Animals were maintained on a commercial feed and water ad libitum. Animals were maintained on a 12-h alternating cycle of light and dark at 23 C. Four lactating dairy goats (40 to 60 kg and 2 to 3 mo postpartum) were purchased from local herds. The goats were fed a commercial dairy concentrate twice daily during milking and provided alfalfa hay and water ad libitum. Animals were milked at 12-h intervals.
Preparation and Administration of Aflatoxin
BI. Ring-labeled [14C]-Aflatoxin B1 was prepared from cultures of Aspergillus parasiticus (ATCC 15517) supplemented with [1-14C] acetate (50 mC1/mmol-) according to the procedure of Hsieh and Mateles (1971) . Purification of AFBI was performed by low-pressure preparative chromatography as previously described (Wong, 1982) . Specific activity and radiochemical purity were determined after one-step thin-layer chromatography (TLC) on silica gel plates developed with chloroform:acetone:isopropanol (85:15:2.5 v/v). Quantification of AFBI was based on fluorescence using a spectTodensitometer and AFB1 standards. Radioactivity was determined by scintillation counting. Radiochemical purity was 95% or greater for all preparations.
The 
Sample Collection. After administration of
[14C]-AFB1, rats were housed in plastic metabolism cages for 6 h to enable collection of urine and feces. Urine was kept on ice. After 6 h, animals were anesthetized with diethyl ether. Blood was collected via cardiac puncture. Rats were then killed and tissues removed for bound, aqueous-and dichloromethane-soluble metabolite analyses. Blood and tissues were kept on ice until homogenized for analysis.
Goats were housed in metabolism cages for 120 h after administration of [14C]-AFB1. Urine and milk samples were collected at 6-h intervals for the first 36 h and at 12-h intervals thereafter. Feces were collected at 12-h intervals and were free of urine. When [14C]-AFBI was administered iv, blood was collected after 2, 4, 6, 8, 10, 20, 30, 45, 60 and 90 min; 2, 4, 6, 8, 12, 18 and 24 h; and 12-h intervals thereafter. Blood was sampled 1/2, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 30 and 36 h and at 12-h intervals after oral administration of [14C]-AFB1 Blood samples were stored at 0 to 4 C. Blood kinetic curves were calculated using nonlinear regression techniques (Dixon, 1981) . Milk and urine samples were stored frozen. After 120 h, the goats were killed with phenobarbitol. Tissues were removed and stored until analyzed.
Rat Tissue Analyses. Total radioactivity of whole blood was determined by oxidation of 300-mg samples in a 305 Tri-carb sample oxidizer 4 followed by scintillation counting in Liquiscint s.
[14C]-toluene was used as internal standard.
Mammary glands plus milk were homogenized in an equal weight of water with a Polytron 6 homogenizer. Approximately 400 mg of homogenate were oxidized to determine total radioactivity. Extractions to determine bound, aqueous-and dichloromethane-soluble fractions were performed on duplicate, 1.5-g samples of homogenates. Homogenate samples were diluted with 2.0 ml of water and 1.0 ml of methanol to precipitate macromolecules. This mixture was extracted three times with 3.0 ml of dichloromethane. The dichloromethane was evaporated under gently flowing nitrogen. Total dichloromethane-extractable laC was determined in one duplicate. Residue from the other duplicate was resuspended in 10 ml of dichloromethane:hexane (1 : 1) and added to a 15-mm • 40-cm open column containing 2.0 g of silica gel. The column was washed with 20 ml each of glacial acetic acid:toluene (9:1), ether:hexane (1:1) and diethyl ether:hexane: acetonitrile (3:6:1). Aflatoxins were eluted with 40 ml of dichloromethane:acetone (3:1). Eluents were evaporated to dryness, resuspended in dichloromethane, transferred to vials and evaporated to dryness under N 2. The samples were dissolved in 100 /al of benzene:acetonitrile (98:2); 25/~1 were spotted on a scored TLC plate. Authentic standards of AFB1, AFMI, AFQ1 and aflatoxical (AFL) were spotted for (co-chromatographic) reference. Two-step development of TLC plates was performed using diethyl ether followed by chloroform:acetone:isopropanol (85:15 :
2.5). Metabolites were scraped from the TLC plate with a razor blade and transferred to scintillation vials with 200 bd water and an aqueous fluor s for scintillation counting. Respective recoveries of aflatoxins AFB x and AFM 1 in this procedure were 85 + 4 and 65 +6%.
The aqueous fraction remaining after dichloromethane extraction was counted to estimate water-soluble metabolites. The insoluble residue was separated by centrifugation at 1,000 • g for 10 min, oxidized and counted as described for blood to estimate bound metabolites.
Liver, gut plus feces, and kidneys were weighed and homogenized as described for the mammary glands. Homogenates were analyzed for total, bound, water and dichloromethaneextractable radioactivity using the method described for mammary tissue. Fecal metabolites were isolated and identified as described for mammary plus milk. Total radioactivity in urine was determined directly in Liquiscint s. The dichloromethane-soluble fraction from urine was prepared as described for mammary gland homogenates.
Goat Tissue Analysis. Total radioactivity in milk was determined by liquid scintillation counting of 2.0 ml of milk in 10 ml liquiscint. Milk was extracted for water-and dichloromethane-soluble components by diluting 2.0 ml of milk with 2.0 ml of water and 1.0 ml of methanol, and extracting three times with 3.0 ml of dichloromethane. The dichloromethane fraction was removed, evaporated under N2, resuspended in 1.0 ml of dichloromethane and counted. The aqueous fraction was removed and a sample was counted. The (insoluble) bound fraction was oxidized and counted as described previously. A 50-ml aliquot of milk was used to determine dichloromethane-soluble metabolites by the method of Fukayama et al. (1980) . Aqueous-soluble and dichloromethane-extractable radioactivity in urine were determined as described for milk. One-step TLC analysis of AFB1, AFM1, AFQ1 and AFL were performed on the dichloromethane extract of 2.0 ml of urine.
Dried, ground fecal (300 mg) samples were suspended in 4.0 ml of water and 1.0 ml of methanol prior to three extractions with 2 ml of dichloromethane. All samples were highly colored and could not be counted directly. Therefore, the bound, aqueous-and dichloromethane-extractable fractions were oxidized prior to counting. Metabolite analyses were performed as described for rat mammary tissue.
Liver, kidney, spleen, heart, fat and abdominal muscle samples were collected, weighed and homogenized. Aliquots were oxidized and counted.
Results and Discussion
Recovery of 14C from [14C]-AFBI administered to rats was greater than 80% and independent of route of administration (table  1) . Biotransformations of AFB1 also were independent of route of administration with the exception that radioactivity in the aqueous fraction of mammary tissue plus milk was higher (P<.05) when [14C]-AFBI was administered orally. Seventy to 75% of [14C]-AFB1 administered appeared in urine and gut plus feces within 6 h (table 1). These excretion data are consistent with data obtained with male Fischer rats (Rice, 1984) .
Total radioactivity in mammary tissue plus milk was 2.0 (iv) and 2.6% (oral) of [14C]-AFB1 administered. In mammary tissue plus milk, .75, .41 and .74% of 14C administered iv was recovered in the dichloromethane, aqueous and bound fractions, respectively. Respective distribution among these fractions was .74, 1.18
and .59% when the [14C] -AFB 1 was administered orally. The only metabolite of AFB1 recovered from mammary tissue plus milk was AFM1. The reason why greater quantities of water-soluble metabolites of AFB1 appeared in milk after oral administration is not clear.
Approximately 10% of the 14C from [14C]-AFB1 was recovered from urine. Of this, 80% was in the aqueous fraction and 20% was in the dichloromethane fraction. Sixty to 65% of 14C administered was recovered from gut plus feces. About one-half of this was bound and equal portions of the remainder were recovered in the aqueous and dichloromethane fractions. About 60% of the 7 to 10% of the laC administered that was recovered in liver was in the bound fraction. One to 1.3% and .3 to .5% of 14C administered were recovered in the aqueous and dichloromethane fractions from liver of the rat. When [14C]-AFB1 was administered iv, there was a rapid decline of 14 C in blood within the first hour (figure 3). The best-fit curve for the intravenous data is AFB1 equivalents (ng) = 7.82 x e -1.65t + 2.09 x e --0095t. Values of the half-life (T 89 of the fast-disappearance phase were 25 min and for the second portion of the curve, 72 h. After 48 h, more than 90% of radioactivity associated with whole blood was bound. Dichloromethaneextractable radioactivity declined rapidly and was not detected in blood after 2 h. Aflatoxin BI, AFM1, AFQI and AFL were detected in blood from both iv-dosed animals. These metabolites were not detected after 90 min. Aflatoxin Ql was detected in highest concert- trations followed by AFL and AFM1. Aflatoxin remained in whole blood for the longest period of time. Low molecular weight, water-soluble metabolites comprised about 10% of radioactivity in blood and dropped to near background levels after 24 h. Dichloromethane-soluble metabolites were not detected in blood of animals administered [14C]-AFB orally.
Animals receiving [14C]-AFB1 orally had detectable radioactivity in blood within 30 min (figure 3). Radioactivity increased up to 36 h and decreased slowly thereafter. The best-fit equation (Dixon, 1981) for the declining portion of the curve (48 to 120 h) is AFBI equivalents (rig) = 1.13 x e--.0096t. The T1A for this curve was 72 h, as was observed for the second portion of the iv curve. Radioactivity in blood during this period was in the bound fraction, indicating that high molecular weight AFB1 metabolites in blood have a T% of 72 h.
Liver contained more radioactivity than any other tissue 120 h after administration. Percentages recovered were 7.3 and 4.9 after iv and oral administration, respectively. More than 90% of liver radioactivity was associated with macromolecules. Kidney contained .11% of [14C]-AFB1 administered, while heart, lung and spleen all contained less than .1%. Values in percentage of administered dose after 12 h for these tissues are given in table 4.
Excretion patterns of [14C] .AFB1 in lactating rats and goats are similar. In both species, there is almost complete metabolism. The major route of elimination is via feces with 50 to 70% being excreted in the goat and 48 to 78% in gut plus feces in the lactating rat. The transfer of radioactivity to feces by both species is presumably via biliary secretion. Aflatoxin B1 in feces was low at 2.6% of the oral dose in both species. This implies that at least 97% of the AFB1 that was administered orally was absorbed and metabolized. Engel and Hagemeister (1978) only recovered 15% of AFB1 administered into the rumen of cattle at the duodenum, suggesting significant rumen metabolism. The similarity between patterns of excretion of oral and iv doses in both species used in the present study does not support this observation. The bulk of the radioactivity recovered in fecal samples was similar after iv and oral administration, indicating liver metabolism and excretion via bile. It has been demonstrated that aflatoxins secreted via bile are not reabsorbed in nonlactating rats (Wong, 1982) .
In general, quantities of AFB1 metabolites eliminated via feces in this experiment were similar to amounts excreted by nonlactating CTrace; Trace is defined as dpm detected greater than four times but less than 10 times background in a 12.5-ml sample of whole goat milk. minor elimination route. The process of milk synthesis and secretion actually concentrates AFMI from blood against a concentration gradient. Cummulative recovery of AFB1 metabolites in milk after 120 h was approximately 1%. Over one-half of radioactivity detected in milk was dichloromethane-extractable; nearly all of this can be accounted for as AFMI if the values presented are corrected for recovery. In the two goats, which received the oral dose of [14C]-AFB1, AFQ1 and AFL were detected in trace quantities in milk. The lactating goat is capable of synthesis of AFQ1
and AFL as indicated by isolation of these from the blood of animals administered the iv dose. These levels are extremely low, less than 10 pg/ml milk, and should not be considered a potential human health hazard. Aflatoxin M1 concentrations were two to three orders of magnitude greater, and thus, AFM1 is the metabolite of primary concern. Fecal and urinary excretion of orally administered [14C]-AFBI in lactating SpragueDawley rats and male Fischer rates after 6 h were not significantly different (Rice, 1984) . Thus, lactation and route of administration do not appear to alter the metabolism and elimination of AFBI (table 1) . Urinary excretion in the lactating goats was greater than observed in rats (assuming that most metabolism is over after 6 h in rats). The cause of this species difference may be greater conjugation capacity in the lactating goat.
Tissue levels of [14C] -AFB1 metabolites 120 h after dosing were low in the goats. Liver had the greatest concentration of any tissue analyzed with 12-ppb AFBI equivalents, on the average. The majority of this was bound (greater than 90%). Human risk associated with this residual has not been elucidated and needs further study. After the oral dose, muscle contained only .48% of the dose and 2.58% from an iv dose. The reason for this difference may be the greater dpm/ml remaining in the blood from the iv dose.
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